SYNCRATIC THERAPIES LLC
At Syncratic Therapies LLC, we developed the Melascend® approach to integrate a wealth of nutritional data. Our goal was to avoid the path most often followed by diet supplement companies that formulate "nonspecific" products which you have all seen, "... that have not been evaluated by the FDA to treat, cure, or ameliorate symptoms of any particular disease, disorder, or condition". In contrast, the Melascend® approach is data-driven and compiles data from numerous evidence-based interventions, to utilize specific nutrients in specific ways. Unfortunately, such a product that claims to have a particular therapeutic effect must first gain FDA approval, through a rigorous program of standardized, double-blind, placebo-controlled studies. For a nutraceutical product such as Melascend®, this path quickly became bogged down with conflicting rhetoric on the part of industry "experts", and was unmanageable.
Fortunately for our company, the concept of personalized medicine had emerged in recent years, that is particularly applicable for nutraceutical products, wherein the typical double-blind, placebo-controlled study may not be the most reliable indicator of specific needs for each individual.
At Syncratic Therapies LLC, we have embarked on a new path to enable personalized medicine by utilizing the unique skill sets of our founder, Dr. David Kossor, who has training in Pharmacy, Pharmacology, and Toxicology. The Melascend® concept enables a specific nutraceutical to be compounded based upon specific attributes of a single patient, as provided by the patient's physician. Indeed, the product (Melascend®) can be administered to the patient under the supervision of his or her physician and family, when specific behavioral and cognitive indices can be measured and monitored over time. Importantly, improvements in these indices provides direct evidence that deficiencies of these key nutrients contained in Melascend® play important roles in the progression of the patient's symptoms, and the caregivers can elect to continue to manage the patient on Melascend® as long as therapeutic benefits are realized. In this way, the nutritional status of each patient can be assessed, and a specific therapeutic regimen can be developed for that individual patient.